NutriBand Inc.

Overview

Compare with Anteris Technologies Global Corp., CollPlant Biotechnologies Ltd or ENvue Medical, Inc., or pick any stock.

• TickerNTRB on Nasdaq²
• IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies²
• HeadquartersOviedo, United States²
• Incorporated inNV⁴
• Business address121 S. Orange Ave., Suite 1500, Orlando, Fl 32801⁴
• Filer category, Emerging growth company⁴
• Legal formProfit Corporation²
• LEI549300OZV3WLQQWOD724²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O Incorp Services, Inc., 89169 Las Vegas, United States²

See how the biggest companies compare on our leaderboards

Preclinical phase . Before a drug company can test an experimental treatment in humans, it must prove the drug is safe and effective in animals. Scientists run tests in various animals before presenting the data to the FDA as an investigational new drug application. For already approved drugs, an animal study may not be required prior to testing in humans. In most cases, the company must file an Investigational New Drug (IND) submission to get clearance to test the product in humans.⁵ From its latest annual report

Corporate structure

NutriBand Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NutriBand Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Property

We do not own any real property. We lease under a one year lease an office for $ 2,500 per month at 121 South Orange Street, Orlando, Florida. With the office lease, we have access to boardrooms, kitchen facilities and administrative support services. We lease manufacturing space in Cherryville, North Carolina, for $3,000 per month under a three-year extension lease entered into on February 1, 2025.

Item 2 of the 10-K filed Apr 29, 2026.⁵

Leadership

Who has led NutriBand Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerGareth Sheridan May 22, 2017 to now¹⁶
• ChairSerguei Melnik Feb 10, 2022 to Mar 8, 2023¹⁷
• ChairVitalie Botgros May 22, 2017 to May 22, 2017¹⁸
• PresidentSerguei Melnik Feb 10, 2022 to now¹⁷
• Chief financial officerGerald Goodman Mar 25, 2024 to now¹⁹
• Chief financial officerSerguei Melnik May 22, 2017 to Jun 3, 2019²⁰

Timeline

1. Sep 23, 20268-K Regulation FD disclosure²²
2. Jun 22, 20268-K Entered a material agreement²³
3. Apr 7, 20268-K Regulation FD disclosure²⁴
4. Feb 13, 20268-K Regulation FD disclosure²⁵
5. Feb 3, 20268-K Shareholder vote²⁶
6. Dec 30, 20258-K Regulation FD disclosure²⁷
7. Oct 28, 20258-K Regulation FD disclosure²⁸
8. Sep 3, 20258-K Regulation FD disclosure²⁹
9. Aug 7, 20258-K Unregistered sale of shares; Bylaws or fiscal year changed³⁰
10. Jul 16, 20258-K Bylaws or fiscal year changed³¹
11. Apr 9, 20258-K Regulation FD disclosure³²
12. Feb 13, 20258-K Regulation FD disclosure³³
13. May 22, 2017New chief executive Gareth Sheridan becomes CEO¹⁶

Calendar

Coming up

1. Dec 9, 2026Reports results for the quarter ending Oct/2026³⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

144 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 45 major events, 19 insider forms, 7 large holders, 51 other. The latest 20:

1. Sep 30, 202625-NSE EDGAR
2. Sep 23, 20268-K CURRENT REPORT EDGAR
3. Sep 15, 2026SCHEDULE 13D/A EDGAR
4. Sep 4, 202610-Q QUARTERLY REPORT EDGAR
5. Jun 22, 20268-K CURRENT REPORT EDGAR
6. Jun 11, 202610-Q QUARTERLY REPORT EDGAR
7. May 18, 202610-K/A AMENDMENT NO. 1 TO FORM 10-K EDGAR
8. Apr 29, 202610-K ANNUAL REPORT EDGAR
9. Apr 7, 20268-K CURRENT REPORT EDGAR
10. Feb 13, 20268-K CURRENT REPORT EDGAR
11. Feb 13, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
12. Feb 3, 20268-K CURRENT REPORT EDGAR
13. Dec 30, 20258-K CURRENT REPORT EDGAR
14. Dec 19, 2025DEF 14A PROXY STATEMENT EDGAR
15. Dec 11, 202510-Q QUARTERLY REPORT EDGAR
16. Nov 25, 20255 EDGAR
17. Oct 28, 20258-K CURRENT REPORT EDGAR
18. Oct 21, 20255 EDGAR
19. Oct 20, 2025424B3 PROSPECTUS SUPPLEMENT EDGAR
20. Sep 9, 202510-Q QUARTERLY REPORT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Gareth SheridanSCHEDULE 13D/A, 3 filings Feb 12, 2024 to Sep 15, 2026³⁵
• Serguei MelnikSCHEDULE 13D, 2 filings Feb 13, 2024 to Mar 13, 2025³⁶
• -. Jetservices Lda T.i.i.SC 13D/A, 2 filings Jan 23, 2024 to Sep 19, 2024³⁷

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How NutriBand Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARNutriBand Inc.¹
• CIK0001676047
• Employer ID (EIN)81-1118176⁵
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inNevada⁵
• Fiscal year endsJanuary 31¹
• Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address121 S. Orange Ave., Suite 1500, Orlando, FL 32801¹
• Phone407 377-6695¹
• Shares outstanding12,155,683 as of Sep 4, 2026¹⁴
• Public float$35.1M as of Jul 31, 2025⁵
• AuditorSadler, Gibb & Associates, LLC, Draper, UT PCAOB ID 3627; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceJun 2, 2016¹
• Filings261 in all: 8-K (74), 10-Q (31), S-1/A (14), 5 (13), 4 (11), 424B3 (11), 10-K (10), CORRESP (10)¹
  All 41 form types

  POS AM (8), UPLOAD (7), 8-K/A (6), DEF 14A (6), EFFECT (6), 10-12G/A (4), 424B4 (4), NT 10-Q (4), S-1 (4), D (3), DRS/A (3), RW (3), 10-K/A (2), 4/A (2), 5/A (2), DEF 14C (2), DRS (2), NT 10-K (2), SC 13G (2), SCHEDULE 13D (2), 10-12G (1), 25-NSE (1), 3 (1), 8-A12B (1), CERT (1), DEL AM (1), FWP (1), PRE 14A (1), S-8 (1), S-8 POS (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13D/A (1)

• Latest filingsAnnual report (10-K) Apr 29, 2026
  Quarterly report (10-Q) Sep 4, 2026
  Proxy statement (DEF 14A) Dec 19, 2025
  Latest 8-K (8-K) Sep 23, 2026

Securities registered for trading

From the cover page of the 10-K filed Apr 29, 2026 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks NutriBand Inc. names in Item 1A of its 10-K filed Apr 29, 2026: 22 risks under these headings, as written.⁵

• Risks Concerning our Business
• Before we can market in the United States any product which is classified by the FDA as a drug, we must obtain FDA marketing approval.
• Risk of increased tariffs on foreign goods.
• Our ability to finance our operations and generate revenues depends on the clinical and commercial success of our abuse deterrent fentanyl transdermal system and our other related product candidates, and failure to achieve such success will negatively impact our business.
• If we or any third-party manufacturer fails to comply with FDA current good manufacturing practices, we may not be able to sell our products until and unless the manufacturer becomes compliant.
• If the FDA implements Risk Evaluation and Mitigation Strategies policies for any of our proposed products, we will need to comply with such policies before we can obtain FDA approval or the product.
• We must continually monitor the safety of our products once approved and marketed for potential adverse events which could jeopardize our ability to continue marketing the products.
• If we obtain FDA approval to market our products, we expect to spend considerable time and money complying with federal and state laws and regulations governing their sale, and, if we are unable to fully comply with such laws and regulations, we could face substantial penalties.
• Before we can market our products outside of the United States, we will need to obtain regulatory approval in each country in which we propose to sell our products.
• If we do not have sufficient product liability insurance, we may be subject to claims that are in excess of our net worth.
• Because some of the patches we are developing, such as our abuse deterrent fentanyl patch, have potential severe side effects, we may face liability in the event patients suffer serious, possibly life-threatening, side effects from our products.
• The drug delivery industry is subject to rapid technological change, and our failure to keep up with technological developments may impair our ability to market our products.

Legal proceedings

The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

Currently, there are no pending hearings or motions, and the case is in the discovery stage. In early 2024, the plaintiffs proposed a settlement offer of $100,000. The Company has not responded to that settlement offer.

The opening of Item 3, Legal Proceedings.⁵